Allogeneic CAR-T Cell Therapy (Beijing GoBroad Hospital)

N/A

Report date: 2025/09/15 20:01:49

Base Information

Drug NameAllogeneic CAR-T Cell Therapy (Beijing GoBroad Hospital)
Drug Alias NameOL-CD19-GDT
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing GoBroad Hospital
China Registration ClassN/A

Develop Information

Active CompaniesBeijing GoBroad HospitalOverland ADCT BioPharma
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicSjogren's Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A